Cancer Treatment Reviews
Volume 25, Issue 6 , Pages 323-331 , December 1999

Cancer treatment: the last 25 years

References 

    REFERENCES
  1. Cancer Survival trends in England and Wales, 1971–1995: deprivation and NHS Region. Series SMPS No 61.
  2. Crowther D. Blood and Neoplastic Diseases, A rational approach to the chemotherapy of human malignant disease-I. BMJ. 1974;4:156–159
  3. Gee TS, Yu KP, Clarkson BD. Treatment of adult acute leukemia with arabinosyl cytosine and thioguannine. Cancer. 1969;23:1019
  4. DeVita VT, Serpick A A and Carbone PO. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970;73:881–895
  5. McElwain, T. J. Wrigley, P. F. M. Alice, Hunter, Crowther, D. Malpas, J. S. Peckham Michael, J. Smithers D W and Hamilton Fairley, G. Combination chemotherapy in advanced and recurrent Hodgkin’s disease – Discussion. NCI Monograph No. 36. International symposium on Hodgkin’s disease, 402.
  6. Santoro A and Bonadonna G. Prolonged disease-free survival in MOPP-resistant Hodgkin’s disease after treatment with Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD). Cancer Chemotherapy and Pharmacology. 1979;2:101–105
  7. Bonadonna G, Uslenghi C, Zucali R. Recent trends in the medical treatment of Hodgkin’s disease. European Journal of Cancer. 1975;11:251–266
  8. Guinee, V. F. Giacco, G. G. Durand, M. van den Blink, J. W. Gustavsson, A. Zewuster, R. Dische, S. Fahey T and Lane, W. Journal of Clinical Oncology 1991;9: 947–953.
  9. Frei E. Curative Cancer Chemotherapy. Cancer Research. 1985;45:6523–6537
  10. Vogelzang NJ. Continuous infusion chemotherapy: A critical review. Journal of Clinical Oncology. 1984;2:1289–1304
  11. Jaffe N, Frei E, Traggis D, Bishop Y. Adjuvant Methotrexate and Citrovorum-Factor Treatment of Osteogenic Sarcoma. The New England Journal of Medicine. 1974;291:994–1000
  12. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. The New England Journal of Medicine. 1986;314:1600–1606
  13. Nachman J, Simon MA, Dean L, Shermeta D, Dawson P, Vogelzang J. Disparate histologic responses in simultaneously resected primary and metastatic osteosarcoma following intravenous neoadjuvant chemotherapy. Journal of Clinical Oncology. 1987;15:1185–1190
  14. Fisher B, Carbone P, economou SG. L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. New England Journal of Medicine. 1975;295:117–122
  15. Bonadonna G, Brusamolino G, Valagussa P. combination chemotherapy as an adjuvant treatment in operable barest cancer. New England Journal of Medicine. 1976;294:405–410
  16. Bush H. Adjuvant chemotherapy: an approach to the management of malignant disease. British Journal of Hospital Medicine. 1978;20:260–266
  17. Lancet. 1992;339:1–15: 71–85
  18. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Goodman PJ. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. New England Journal of Medicine. 1990;322:352–358
  19. McVie JG. Current Areas of Treatment. Seminars in Oncology – Paclitaxel (Taxol). Current Practices and Future Directions in Breast Cancer Management. 1996;23:1–4
  20. McVie JG. Non-Small Cell Lung Cancer: Meta-analysis of Efficacy of Chemotherapy. Seminars in Oncology – Current Perspectives on Cancer Chemotherapy. 1996;23:12–14
  21. Tannock IF. Conventional cancer therapy: promise broken or promise delayed?. Lancet. 1998;351:9–16
  22. Ongerboer de Visser BW, Somers R, Nooyen WH, van Heerde P, Hart AMM. Intraventricular Methotrexate Therapy of Leptomeningeal Metastases from Breast. Carcinoma Neurology (Cleveland). 1983;33:1565–1572
  23. Joseph Menczer J, Ben-Baruch G, Rizel S, Brenner H. Intraperitoneal chemotherapy in patients with ovarian carcinoma who are in complete clinical remission. Cancer. 1992;70:1956–1959
  24. Soloway MS. The management of superficial bladder cancer. Cancer. 1980;45:1856–1865
  25. ¡
  26. Workman P. Pharmacokinetics of hypoxic cell radiosensitizers. Cancer Clinical Trials. 1980;3:237–251
  27. Schaake-Koning, C. Van der Bogaert, W. Dalesio O et al. Effect of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N England J Med, 326
  28. Monaghan J. Time to add chemotherapy to radiotherapy for cervial cancer. The Lancet. 1999;353:1288
  29. Leyland-Jones B, Shak S. Addition of Herceptin (Humanized Anti-Herz Antibody) to first line chemotherapy for Herz overexpressing metastatic breast cancer (Herz+/MBC) Markedly increases anticancer activity-A randomized multinational controlled Phase III Trial. Proceedings of ASCO. 1998;17:98a

PII: S0305-7372(99)90136-6

doi: 10.1053/ctrv.1999.0136

Cancer Treatment Reviews
Volume 25, Issue 6 , Pages 323-331 , December 1999

Article Tools